1.     Fujita R., Blot V., Wong E., Stewart C., Lieuw V., Richardson R., Banah A., Villicana J., Timmer A., Coronella J., Newman R. & Gymnopoulos M. “A novel non-agonist c-Met antibody drug conjugate with superior potency over a c-Met tyrosine kinase inhibitor in c-Met amplified and non-amplified cancers”.  Cancer Biology & Therapy 21 (4) online Mar 19 (2020)

2.     Gymnopoulos M., Betancourt O., Blot V., Fujita R., Galvan D., Lieuw V., Nguyen S., Snedden J., Stewart C., Villicana J., Wojciak J., Wong E., Pardo R., Patel N., D’Hooge F., Vijayakrishnan B., Barry C., Hartley J., Howard P., Newman R., and Coronella J.  “TR1801-ADC: a highly potent cMet antibody–drug conjugate with high activity in patient-derived xenograft models of solid tumors.” Molecular Oncology 14, 54–68 (2020)

3.     Blot V., Richardson R., Coronella J. “The new generation of antibody drug conjugates” Forum on Immunopathological Diseases and Therapeutics: New Immunological Approaches to Cancer Therapy. 5 (1-2) 25-45 (2014)

4.     Lyman M., Lieuw V., Richardson R., Timmer A., Stewart C., Granger S., Woods R., Silacci M., Grabulovski D., Newman R. “A bispecific antibody that targets IL-6 receptor and IL-17A for the potential therapy of patients with autoimmune and inflammatory diseases.” J. Biol. Chem. 293(24) 9326-9334 (2018)

5.     Michael Lyman, Vincent Lieuw, Robyn Richardson, Christine Stewart & Roland Newman. MT-6194: A novel bi-specific therapeutic targeting IL-6R and IL-17A.  Antibody Engineering & Therapeutics Conference, San Diego, (2016)

6.     Gymnopoulos M., Betancourt O., Blot V., Fujita R., Ly D., Nguyen S., Snedden J., Villicana J., Wojciak J., Wong E., Pardo R., Patel N., D’Hooge F., Vijayakrishnan B., Barry C., Hartley J., Howard P., Newman R., and Coronella J. TR1801-ADC, an optimized anti-Met PBD ADC with high efficacy in solid tumors of the GI tract and head and neck. AACR Annual Meeting, Atlanta 2019)